Gene Therapy-Focused Lexeo Therapeutics Eyes $126M IPO
Gene therapy-focused biotechnology firm Lexeo Therapeutics Inc. on Monday unveiled plans for an estimated $126 million initial public offering, represented by Cooley LLP and underwriters counsel Paul Hastings LLP, joining a...To view the full article, register now.
Already a subscriber? Click here to view full article